Earnings Call Summary | Steris PLC(STE.US) Q4 2024 Earnings Conference
Earnings Call Summary | Steris PLC(STE.US) Q4 2024 Earnings Conference
The following is a summary of the STERIS Plc (STE) Q4 2024 Earnings Call Transcript:
以下是STERIS Plc（STE）2024年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
STERIS Plc reported total Q4 revenue growth of 10%, with adjusted earnings per diluted share at $2.58.
Full year revenue growth reached 12%, with adjusted earnings per share at $8.83.
Gross margin for the quarter declined to 42.6% while EBIT margin decreased to 23.7%.
Capital expenditures totaled $360 million while the total debt sat at $3.2 billion, with a debt-to-EBITDA ratio of 2.1.
Free cash flow was $620 million for the fiscal year 2024.
STERIS Plc報告稱，第四季度總收入增長了10％，調整後的攤薄後每股收益爲2.58美元。
全年收入增長達到12％，調整後的每股收益爲8.83美元。
該季度的毛利率下降至42.6％，而息稅前利潤率降至23.7％。
資本支出總額爲3.6億美元，總債務爲32億美元，債務與息稅折舊攤銷前利潤的比率爲2.1。
2024財年的自由現金流爲6.2億美元。
Business Progress:
業務進展：
The Healthcare segment achieved 13% constant currency organic revenue growth, showing continuous progress.
They expect growth in AST, Healthcare, and Life Sciences segments in the upcoming fiscal year.
STERIS provided FY 2025 projections, expecting a 6.5% to 7.5% increase in as-reported revenue.
A targeted restructuring plan is announced, which includes the restructuring of the Healthcare Surgical Capital business in Europe and other actions.
The company decided to divest two businesses during the year, including the Dental segment.
醫療保健板塊實現了13％的固定貨幣有機收入增長，顯示出持續的進步。
他們預計，在下一個財年，AST、醫療保健和生命科學板塊將實現增長。
STERIS提供了2025財年的預測，預計報告的收入將增長6.5％至7.5％。
宣佈了一項有針對性的重組計劃，其中包括重組歐洲醫療外科資本業務和其他行動。
該公司決定在年內剝離兩項業務，包括牙科板塊。
More details: Steris PLC IR
更多詳情： Steris PLC 紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。